CureVac shares have been volatile over the past week, gaining some 25%. The stock has seen increased trading volume following ...

CureVac recently released new clinical data. Why should investors care? Click here to find out why I am bullish on CVAC stock ...

Leerink Partners has recently reduced CureVac BV (CVAC) stock to Market Perform rating, as announced on April 25, 2024, according to Finviz. Earlier, on June 8, 2023, SVB Securities had initiated the ...

Shares of CureVac are trading higher by 15% during Monday's session. The stock is gaining following a CDC report highlighting ...

Jefferies sees Arbutus (NASDAQ:ABUS) potentially benefitting from vaccines being developed by Moderna (MRNA) and Pfizer (PFE) ...

Novavax (NVAX) and other vaccine developers rise as Investors react to rising flu and COVID-19 cases in the U.S. Read more ...

CureVac BV (CVAC) stock saw a modest uptick, ending the day at $4.44 which represents a slight increase of $0.82 or 22.65% from the prior close of $3.62. The stock opened at $4.14 and touched a low of ...

In rural Virginia, a single land transfer is a first step toward correcting a long history of land loss for Black Southern ...

Moderna stock ( MRNA) fell over 9% on Wednesday, forfeiting most of its gains from Tuesday's session during a volatile week for the stock seen after the first reported bird flu death in the US, which ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Moderna stock was on track to see a weekly gain of over 20% as of Wednesday following the first reported bird flu death in the US.